Metabolic deactivation by cytochrome P450 (CYP) is considered a potential mechanism of anticancer drug resistance. However, this hypothesis is predominantly based on indirect pieces of evidence and/or is influenced by interfering factors such as the use of multienzymatic models. Thus, an experimental approach for its verification is needed. In the present work, we employed HepG2 cells transduced with CYP enzymes involved in docetaxel, paclitaxel and vincristine metabolism to provide mechanistic evidence on their possible roles in resistance to these chemotherapeutic agents. Using MTT proliferation tests, we showed that overexpression of CYP3A4 resulted in decreased antiproliferative activity of 1 μM docetaxel (by 11.2, 23.2 and 22.9% at 24, 48 and 72 h intervals, respectively), while the sensitivity of CYP3A4-transduced cells was restored by co-administration of ketoconazole. Paclitaxel exhibited differential efficacy in CYP2C8- and empty vector-transduced cells (significant differences between 10.9 and 24.4% for 0.01, 0.1 and 1 μM concentrations), but neither montelukast nor clotrimazole was capable of affecting this asymmetry. Finally, the pharmacological activity of vincristine was not influenced by CYP3A4 or CYP3A5 overexpression. In the follow-up caspase activation assays, docetaxel was confirmed to be a victim of CYP3A4-mediated resistance, which is, at least partly, brought by impaired activation of caspases 3/7, 8 and 9. In summary, our data demonstrate that CYP3A4-mediated metabolic deactivation of docetaxel might represent a significant mechanism of pharmacokinetic resistance to this drug. In contrast, the possible role of CYPs in resistance to paclitaxel and vincristine has been disconfirmed. Importantly, the expression of CYP3A4 in HepG2_CYP3A4 cells is comparable to that in primary hepatocytes and HepaRG cells, which suggests that our results might be relevant for in vivo conditions, e.g., for hepatocellular carcinoma. Thus, our data may serve as a valuable in vitro background for future in vivo studies exploring the area of intratumoural metabolism-based drug resistance.

Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic

Division of Biochemical Toxicology National Center for Toxicological Research U S FDA 3900 NCTR Road Jefferson AR 72079 USA

Zobrazit více v PubMed

Zanger UM, Schwab M, Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacol. Ther 138 (2013) 103–141. PubMed

Manikandan P, Nagini S, Cytochrome P450 structure, function and clinical significance: a review, Curr. Drug Targets 19 (2018) 38–54. PubMed

Shi S, Li Y, Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition, Curr. Drug Metabol 15 (2014) 915–941. PubMed

McFadyen MC, Melvin WT, Murray GI, Cytochrome P450 enzymes: novel options for cancer therapeutics, Mol. Canc. Therapeut 3 (2004) 363–371. PubMed

Michael M, Doherty MM, Tumoral drug metabolism: overview and its implications for cancer therapy, J. Clin. Oncol 23 (2005) 205–229. PubMed

Rochat B, Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents, Curr. Cancer Drug Targets 9 (2009) 652–674. PubMed

Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK, Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes, Curr. Pharmaceut. Des 19 (2013) 7126–7140. PubMed

Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H, Kawamoto T, Expression of cytochrome P450 in tumor tissues and its association with cancer development, Front. Biosci 9 (2004) 1967–1976. PubMed

Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S, Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues, Int. J. Canc 97 (2002) 129–132. PubMed

Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S, Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers, Breast Cancer 12 (2005) 11–15. PubMed

Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA, Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy, Br. J. Canc 87 (2002) 681–686. PubMed PMC

Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH, Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma, J. Clin. Oncol 21 (2003) 2481–2485. PubMed

Gharavi N, El-Kadi AO, Expression of cytochrome P450 in lung tumor, Curr. Drug Metabol 5 (2004) 203–210. PubMed

Baker SD, Sparreboom A, Verweij J, Clinical pharmacokinetics of docetaxel: recent developments, Clin. Pharmacokinet 45 (2006) 235–252. PubMed

Sonnichsen DS, Relling MV, Clinical pharmacokinetics of paclitaxel, Clin. Pharmacokinet 27 (1994) 256–269. PubMed

Vaclavikova R, Horsky S, Simek P, Gut I, Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants, Naunyn-Schmiedeberg’s Arch. Pharmacol 368 (2003) 200–209. PubMed

Jackson DV Jr., Castle MC, Bender RA, Biliary excretion of vincristine, Clin. Pharmacol. Ther 24 (1978) 101–107. PubMed

Yao D, Ding S, Burchell B, Wolf CR, Friedberg T, Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance, J. Pharmacol. Exp. Therapeut 294 (2000) 387–395. PubMed

Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV, Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver, Pharmacogenetics 8 (1998) 391–401. PubMed

Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD, Selective metabolism of vincristine in vitro by CYP3A5, Drug Metab. Dispos 34 (2006) 1317–1327. PubMed

Xuan J, Chen S, Ning B, Tolleson WH, Guo L, Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity, Chem. Biol. Interact 255 (2016) 63–73. PubMed PMC

Chen S, Wu Q, Li X, Li D, Mei N, Ning B, Puig M, Ren Z, Tolleson WH, Guo L, Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity, J Environ Sci Health C Toxicol Carcinog 39 (2021) 68–86. PubMed PMC

Walsky RL, Gaman EA, Obach RS, Examination of 209 drugs for inhibition of cytochrome P450 2C8, J. Clin. Pharmacol 45 (2005) 68–78. PubMed

Vagiannis D, Novotna E, Skarka A, Kammerer S, Kupper JH, Chen S, Guo L, Staud F, Hofman J, Ensartinib (X-396) effectively modulates pharmacokinetic resistance mediated by ABCB1 and ABCG2 drug efflux transporters and CYP3A4 biotransformation enzyme, Cancers 12 (2020). PubMed PMC

Rodriguez-Antona C, Ingelman-Sundberg M, Cytochrome P450 pharmacogenetics and cancer, Oncogene 25 (2006) 1679–1691. PubMed

Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT, Tumor-specific expression of cytochrome P450 CYP1B1, Canc. Res 57 (1997) 3026–3031. PubMed

McFadyen MC, Murray GI, Cytochrome P450 1B1: a novel anticancer therapeutic target, Future Oncol 1 (2005) 259–263. PubMed

Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL, Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Therapeut 296 (2001) 537–541. PubMed

Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB, Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer, J. Clin. Oncol 16 (1998) 187–196. PubMed

Novotna E, Bukum N, Hofman J, Flaxova M, Kouklikova E, Louvarova D, Wsol V, Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile, Arch. Toxicol 92 (2018) 2845–2857. PubMed

Novotna E, Bukum N, Hofman J, Flaxova M, Kouklikova E, Louvarova D, Wsol V, Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): a promising therapeutic target for cancer treatment, Biochem. Pharmacol 156 (2018) 22–31. PubMed

Tavares TS, Hofman J, Lekesova A, Zelazkova J, Wsol V, Olaparib synergizes the anticancer activity of daunorubicin via interaction with AKR1C3, Cancers 12 (2020). PubMed PMC

Morell A, Cermakova L, Novotna E, Lastovickova L, Haddad M, Haddad A, Portillo R, Wsol V, Bruton’s tyrosine kinase inhibitors ibrutinib and acalabrutinib counteract anthracycline resistance in cancer cells expressing AKR1C3, Cancers 12 (2020). PubMed PMC

Hofman J, Sorf A, Vagiannis D, Sucha S, Novotna E, Kammerer S, Kupper JH, Ceckova M, Staud F, Interactions of alectinib with human ATP-binding cassette drug efflux transporters and cytochrome P450 biotransformation enzymes: effect on pharmacokinetic multidrug resistance, Drug Metab. Dispos 47 (2019) 699–709. PubMed

Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, Kupper JH, Chen S, Guo L, Ceckova M, Staud F, Brivanib exhibits potential for pharmacokinetic drug-drug interactions and the modulation of multidrug resistance through the inhibition of human ABCG2 drug efflux transporter and CYP450 biotransformation enzymes, Mol. Pharm 16 (2019) 4436–4450. PubMed

Vagiannis D, Yu Z, Novotna E, Morell A, Hofman J, Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme, Biochem. Pharmacol 178 (2020) 114061. PubMed

Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A, Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel, Clin. Pharmacol. Ther 75 (2004) 448–454. PubMed

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM, Revisiting the role of ABC transporters in multidrug-resistant cancer, Nat. Rev. Canc 18 (2018) 452–464. PubMed PMC

Kathawala RJ, Gupta P, Ashby CR Jr., Chen ZS, The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade, Drug Resist. Updates 18 (2015) 1–17. PubMed

Fujitaka K, Oguri T, Isobe T, Fujiwara Y, Kohno N, Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer, Canc. Chemother. Pharmacol 48 (2001) 42–46. PubMed

Kostrubsky VE, Lewis LD, Strom SC, Wood SG, Schuetz EG, Schuetz JD, Sinclair PR, Wrighton SA, Sinclair JF, Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes, Arch. Biochem. Biophys 355 (1998) 131–136. PubMed

Nallani SC, Genter MB, Desai PB, Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel, Canc. Chemother. Pharmacol 48 (2001) 115–122. PubMed

Garcia-Martin E, Pizarro RM, Martinez C, Gutierrez-Martin Y, Perez G, Jover R, Agundez JA, Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8, Pharmacogenomics 7 (2006) 575–585. PubMed

Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ, Versluis C, Beijnen JH, Isolation, purification and biological activity of major docetaxel metabolites from human feces, Drug Metab. Dispos 24 (1996) 655–658. PubMed

Owellen RJ, Hartke CA, Hains FO, Pharmacokinetics and metabolism of vinblastine in humans, Canc. Res 37 (1977) 2597–2602. PubMed

Leveque D, Jehl F, Molecular pharmacokinetics of catharanthus (vinca) alkaloids, J. Clin. Pharmacol 47 (2007) 579–588. PubMed

Bender RA, Castle MC, Margileth DA, Oliverio VT, The pharmacokinetics of [3H]-vincristine in man, Clin. Pharmacol. Ther 22 (1977) 430–435. PubMed

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo